# EDGAR Filing Document

**Accession Number:** 0001827401
**File Stem:** 0001062993-25-016559
**Filing Date:** 2025-11
**Character Count:** 5719
**Document Hash:** 4270bc35108fd1813d3197ce0a0664df
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-25-016559.hdr.sgml**: 20251107

**ACCESSION NUMBER**: 0001062993-25-016559

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251030

**FILED AS OF DATE**: 20251107

**DATE AS OF CHANGE**: 20251107

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BRIGHT MINDS BIOSCIENCES INC.
- **CENTRAL INDEX KEY:** 0001827401
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40997
- **FILM NUMBER:** 251463113

**BUSINESS ADDRESS:**
- **STREET 1:** 19 VESTRY STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10013
- **BUSINESS PHONE:** 6474072515

**MAIL ADDRESS:**
- **STREET 1:** 19 VESTRY STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10013

------

**UNITED STATES**<br>**SECURITIES AND EXCHANGE COMMISSION**<br>**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of <u>**October 2025**</u>

Commission File No. <u>**001-40997**</u>

<u>**BRIGHT MINDS BIOSCIENCES INC.**</u><br>(Translation of registrant's name into English)

**19 Vestry Street,**<br><u>**New York, NY 10013**</u><br>(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

**Form 20-F [ X ]** Form 40-F **[ ]**

------

**SUBMITTED HEREWITH**

---

| | |
|:---|:---|
| &nbsp;&nbsp;<u>**Exhibits**</u> |  |
| &nbsp;&nbsp;[99.1](exhibit99-1.htm) | [News Release dated October 30, 2025](exhibit99-1.htm) |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| |
|:---|
| **BRIGHT MINDS BIOSCIENCES INC.** |
| (signed) "*Ryan Cheung*" |
| Ryan Cheung |
| Chief Financial Officer |

---

Date: November 7, 2025

------

## Exhibit 99.1

------

**For Immediate Release**

**Bright Minds Biosciences to Present at Upcoming Conferences**

New York City - October 30, 2025 - Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:

**EVENT:** Guggenheim 2nd Annual Healthcare Innovation Conference

**DATE:** Wednesday, November 12, 2025

**TIME:** 9:00am ET

**WEBCAST:** <u>**https://event.summitcast.com/view/6h3HS7z68WnTQE5PS7Vq8J/F9hC9xPJYgD5EJwoHF3vGF**</u>

**EVENT:** Jefferies Global Healthcare Conference in London

**DATE:** Monday, November 17, 2025

**TIME:** 12pm GMT / 7am ET

**WEBCAST:** There is no webcast for this event

The live and archived webcast for the Guggenheim event will be accessible from the Company's website at <u>https://brightmindsbio.com/investors/</u> under Events and Presentation. The replay of the webcast will be accessible for 60 days.

**Grant of Equity Incentive Awards**

The Company has granted stock options (the "Options") to certain directors, officers and consultants of the Company to purchase an aggregate 43,000 common shares (the "Shares") in the capital of the Company pursuant to the Company's share option plan. The Options are exercisable at an exercise price of US$54.47 per Share for a period of five (5) years from the date of grant. The Options are subject to vesting periods over the course of the term of the Options.

**About Bright Minds Biosciences**

Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.

Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

**Contact Information**

Investor Relations

Lisa M. Wilson

T: 212-452-2793

E: <u>lwilson@insitecony.com</u>

Alex Vasilkevich

Chief Operating Officer

Bright Minds Biosciences Inc.

T: 414-731-6422

E: alex@brightmindsbio.com

Website: <u>www.brightmindsbio.com</u>

*The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.* 

*The securities of the Company referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful.*

------